Oxford Biomedica (LON:OXB) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

Shares of Oxford Biomedica plc (LON:OXB) crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of GBX 564.56 and traded as low as GBX 502. Oxford Biomedica shares last traded at GBX 511, with a volume of 349,560 shares.

Analyst Ratings Changes

Several brokerages have recently issued reports on OXB. Royal Bank Of Canada reissued an “outperform” rating and issued a GBX 900 target price on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 target price on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of GBX 613.32.

Oxford Biomedica Stock Up 1.2%

The company has a market cap of £637.92 million, a P/E ratio of -16.49 and a beta of 1.11. The company has a quick ratio of 1.67, a current ratio of 2.21 and a debt-to-equity ratio of 273.08. The company has a fifty day moving average of GBX 492.94 and a 200 day moving average of GBX 564.22.

Oxford Biomedica (LON:OXB) last announced its earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) EPS for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. On average, research analysts anticipate that Oxford Biomedica plc will post -31.08 earnings per share for the current fiscal year.

Insider Transactions at Oxford Biomedica

In related news, insider Roch Doliveux bought 20,250 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The shares were purchased at an average price of GBX 505 per share, with a total value of £102,262.50. 25.83% of the stock is currently owned by insiders.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.